Novartis AG

Swiss Stock Exchange:NOVN.SW

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Switzerland

Market Cap

USD 233.61 B

Share Price

USD 117.76

Avg Daily Volume

4,098,771

Change (1 day)

-0.47%

Change (1 year)

9.97%

Change (YTD)

20.06%

Novartis AG EPS (Diluted) for the year ending December 31, 2024: USD 5.87

Novartis AG EPS (Diluted) is USD 5.87 for the year ending December 31, 2024, a -17.32% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Novartis AG EPS (Diluted) for the year ending December 31, 2023 was USD 7.10, a 123.97% change year over year.
Novartis AG EPS (Diluted) for the year ending December 31, 2022 was USD 3.17, a -70.18% change year over year.
Novartis AG EPS (Diluted) for the year ending December 31, 2021 was USD 10.63, a 201.99% change year over year.
Novartis AG EPS (Diluted) for the year ending December 31, 2020 was USD 3.52, a 14.29% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses

Swiss Stock Exchange: NOVN.SW

Novartis AG

CEO	Dr. Vasant Narasimhan M.D.
IPO Date	Aug. 3, 1995
Location	Switzerland
Headquarters	Lichtstrasse 35
Employees	75,883
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.